With shares of Eli Lilly (LLY 0.84%) gaining an impressive 59% in 2023, it's no secret investors are eager to learn what the company is aiming for in 2024.Happily, there are quite a few clues about what's coming next, including from senior management, and the outlook is bright.The shopping spree will continueWhile speaking at J.P. Morgan's annual healthcare conference on Jan. 9, Eli Lilly CEO David Ricks had a few choice words for the myriad biotech operators in the crowd: "We're open for business on extern ...

In the latest trading session, Eli Lilly (LLY) closed at $628.91, marking a -0.89% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.56%. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq decreased by 0.59%.The drugmaker's stock has climbed by 9.44% in the past month, exceeding the Medical sector's gain of 3.8% and the S&P 500's gain of 1.2%.The investment community will be paying close attention to the earnings performance of E ...

U.S. markets have been stuck in stall mode to kick off the New Year, taking a breather following last year’s historic rally. It looks like we’ll have to wait a bit longer to see the S&P 500 clinch a new all-time high after sellers have stepped in repeatedly through the first two weeks. By my count, twice last week we hit the (closing) high from early 2022 on an intraday basis, but failed to close above the coveted threshold. This could be a temporary sign of exhaustion; buying pressure in the general area a ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned +10.9%, compared to the Zacks S&P 500 composite's +1.6% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has gained 9.4%. The key question now is: What could be the stock's future direction?While media releases ...

For all of its many successes, the healthcare industry isn't exactly a hotbed of dividend-paying stocks. However, this doesn't mean the sector is entirely without companies that remunerate their shareholders. Some of its larger and more established companies not only hand out distributions on a regular basis, they also declared hefty dividend raises heading into 2024.So take a bow, Eli Lilly (LLY 1.13%) and UnitedHealth Group (UNH -3.37%); both of these familiar sector names hiked their payouts at double-di ...

Amid a turbulent year for the US pharmaceutical sector, the iShares U.S. Pharmaceuticals ETF (IHE), tracking major domestic pharma companies, has struggled, recording a meager 1% gain in 2023. However, amid this lackluster performance, Eli Lilly (NASDAQ: LLY) emerged as a standout performer, closing the year with remarkable gains exceeding 60%. Notably, January 2024 underscored the stock’s relentless surge, reaching three all-time highs within a week, with the latest peak at $639.76 on January 11, subsequen ...

jetcityimage Investment Thesis I believe Eli Lilly (NYSE:LLY) is poised for continual growth due to the significant demand for weight-loss drugs and the increasing insurance coverage. My perspective is a belief in the future of GLP-1 therapies, particularly those targeting obesity. My main focus is on Eli Lilly's pioneering drug, Zepbound, which I see tackling weight-related health issues- we could almost think of this new division of obesity management as a growth segment in the company, at least that's ho ...

In the latest trading session, Eli Lilly (LLY) closed at $630.19, marking a +0.75% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.57% for the day. Elsewhere, the Dow saw an upswing of 0.46%, while the tech-heavy Nasdaq appreciated by 0.75%.Shares of the drugmaker have appreciated by 6.96% over the course of the past month, outperforming the Medical sector's gain of 6.86% and the S&P 500's gain of 3.4%.Investors will be eagerly watching for the performance of Eli Lil ...

Skyrocketing 59%. Reaching a market cap of over $550 billion. Vaulting past Johnson & Johnson to become the biggest pharmaceutical company on the planet. No matter how you look at it, 2023 was a pivotal year for Eli Lilly (LLY -0.09%).It might seem logical to think that Lilly's momentum would continue into the new year. But quite a few of the folks who are paid big bucks to follow the company don't think that will happen. Wall Street doesn't expect Eli Lilly stock to move much higher in 2024. However, here' ...

Eli Lilly and Company (NYSE:LLY) JPMorgan 42nd Annual Healthcare Conference January 9, 2024 4:15 PM ET CorporateParticipants Dave Ricks - Chairman and Chief Executive Officer ConferenceCall Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat this afternoon with Eli Lilly. Lilly has obviously had a tremendous few years here and really looking forward to our discussion with Dave Ricks, company's Chairman ...